Travere Therapeutics stock is little changed today, trading near $62.86 while the company announces a leadership transition.
Travere Therapeutics named Bradley Campbell as president and chief executive officer, effective Dec. 1. Campbell's appointment comes as the biopharmaceutical company's president and CEO Eric Dube ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his ...
Janus Henderson Global Life Sciences Fund returned 12.80% and the MSCI World Health Care Index returned 6.75%.
VegFest Kelowna returns to City Park in downtown Kelowna on Sunday, Sept. 20. It brings together local businesses, food vendors, speakers, musicians, non-profit organizations and community members for ...
Travere Therapeutics share news ...
On September 15, 2026, Travere Therapeutics CFO Cline Christopher R. exercised options for 20,000 shares at an exercise price ...
Travere Therapeutics insider Inrig Jula exercised options for 32,395 shares at $8.93 each, followed by the sale of 44,674 ...
Il 15 settembre 2026, Elizabeth E. Reed, Chief Legal Officer e General Counsel, ha venduto 37.500 azioni di Travere Therapeutics per un valore di 2.337.695 USD. In seguito alla presentazione ...
Il 15 settembre 2026, William E. Rote, Chief Research Officer, ha venduto 209.048 azioni di Travere Therapeutics per un valore di 13.135.397 USD. In seguito alla presentazione del Modulo 4 ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.
Officer PETER HEERMA intends to sell 172.72K shares of its common stock on Sep 16, with a total market value of approximately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results